Johnson & Johnson applies for emergency authorization for a single shot vaccine
Johnson & Johnson submitted an application for Emergency Use Authorization of its COVID-19 vaccine candidate to the United States Food & Drug Administration. An outside advisory panel will meet February 26th to determine whether approval should move forward, and if it does the vaccine could be available in the United States for early March. Johnson & Johnson’s candidate showed strong results in clinical trials, with 85% effectiveness in preventing severe disease in the US, South Africa and Latin America. However there were regional differences in preventing moderate to severe infection, with 57% effectiveness in South Africa where a local variant is dominant compared to 72% in the US. The application seeks approval for a single dose regimen of vaccine, which would differ from those currently in use which require two shots.
Published: February 9, 2021
The New York TimesRead Article